Table 3.
Reference | Study design |
Population Sample (n) RA outcomes (n) |
Silica exposure methods | RA outcome methods | Cigarette smoking and other adjustment variables |
Effect size (95% confidence interval) for silica and RA risk |
Comments |
---|---|---|---|---|---|---|---|
Klockars M, Br Med J (1987) [62] | Retrospective cohort | Central and south western Finland, male granite workers aged 15 to 72 years n=1,026 silica-exposed n=35 RA | Dust concentration measured in workplace | 1987 ACR criteria | No smoking adjustment Age, residential area | Incidence of disability pensions for RA: RR 5.08 (3.31-7.79) |
|
Turner S, Occup Environ Med (2000) [65] | Case-control | United Kingdom, pottery, sandstone, and refractory material (aluminosilicate or silica) workers n=290 n=58 RA | Duration of physician-performed occupational history | Physician-diagnosed RA | Smoking status (ever or never) Age, sex, date, occupation, parity, pneumoconiosis | Per 10 years silica exposure and all RA: OR 0.31 (0.16-0.61) |
|
Stolt P, Ann Rheum Dis (2005) [61] | Case-control | Sweden, men aged 18 to 70 years (EIRA Study) n=552 n=276 incident RA | Self-reported exposure to stone dust, rock drilling, or stone crushing | 1987 ACR criteria | Smoking status (ever or never) Age, residential area | All RA: OR 2.2 (1.2-3.9) RF-positive RA: OR 1.9 (0.9-4.0) RF-negative RA: OR 2.1 (0.8-5.1) |
|
Stolt, Ann Rheum Dis (2010) [60] | Case-control | Sweden, men aged 18-70 years (EIRA Study) n=1,236 n=577 incident RA | Self-reported exposure to stone dust, rock drilling, or stone crushing | 1987 ACR criteria | No smoking adjustment Age, residential area | All RA: OR 1.39 (0.98-1.96) ACPA-positive RA: OR 1.67 (1.13-2.48) ACPA-negative RA: OR 0.98 (0.57-1.66) |
|
Yahya A, Mod Rheumatol (2014) [59] | Case-control | Malaysia, males aged 18-70 years (MyEIRA Study) n=362 n=129 incident RA | Self-reported exposure to stone dust, rock drilling, or stone crushing | 1987 ACR criteria | No smoking adjustment Age, sex, residential area | All RA: OR 2.0 (0.9-4.6) ACPA-positive RA: OR 2.4 (1.0-5.6) ACPA-negative RA: OR 0.9 (0.2-4.5) |
|
Blanc PD, Am J Med (2015) [57] | Retrospective cohort | Sweden, male construction workers aged 30 to 84 years n=240,983 n=713 incident RA | Job-exposure matrices | Billing code | Smoking status (ever or never) Age | All RA: RR 1.33 (1.11-1.60) Seropositive RA: RR 1.28 (1.02-1.61) Seronegative RA: RR 1.46 (1.03-2.07) |
|
Vihlborg P, BMJ Open (2017) [58] | Retrospective cohort | Sweden, male iron foundry workers and general Swedish population n=2,187 n=18 seropositive RA | Silica dust measurements for job categories (mg/m3) | Billing code | No smoking adjustment Age, sex, year | Seropositive RA: SIR 1.70 (1.01-2.69) |
|
Ilar A, RMD Open (2019) [50] | Case-control | Sweden, EIRA Study and national registers n=126,534 n=11,285 RA | Job-exposure matrices | 2+ visits for RA and DMARD receipt | Smoking pack-years (continuous) Age, sex, county, year, alcohol use | All RA: OR 1.3 (1.2-1.5) Seropositive RA: OR 1.4 (1.2-1.5) Seronegative RA: OR 1.2 (1.0-1.4) |
|
Statistically significant results are bolded.
ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; DMARD, disease modifying anti-rheumatic drug; EIRA, Epidemiological Investigations of Rheumatoid Arthritis; OR, odds ratio; RA, rheumatoid arthritis; RF, rheumatoid factor; RR, relative risk; SIR, standardized incidence ratio.